[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645627":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":44,"collaborators":19,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":19,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":19,"enrollmentInfo":55,"targetDuration":19,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":70,"whyStopped":19,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Institute of Oncology Ljubljana","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Biomarker Assessment Cohort","Participants with stage III colon cancer receiving neoadjuvant systemic therapy according to routine clinical practice will undergo additional peripheral venous blood sampling at predefined time points for ctDNA and TEP biomarker analysis.",[12],"Procedure: Additional Peripheral Venous Blood Sampling for ctDNA and TEP Biomarker Analysis",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","Additional Peripheral Venous Blood Sampling for ctDNA and TEP Biomarker Analysis","Additional peripheral venous blood samples will be collected at predefined time points before treatment, during systemic treatment, before surgery, and after surgery. Samples will be analyzed for circulating tumor DNA (ctDNA) and tumor-educated platelets (TEP).",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Tanja Mesti, MD","CONTACT","+386 1 5879 287","tmesti@onko-i.si",[27],{"facility":5,"status":19,"city":28,"state":19,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Ljubljana","1000","Slovenia","SI",{"type":33,"coordinates":34},"Point",[35,36],14.50513,46.05108,{"lat":36,"lon":35},[39,40],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"name":41,"role":23,"phone":42,"phoneExt":19,"email":43},"Klavdija Korošec","+38631630065","kkorosec@onko-i.si",{"type":45,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100645627","ctdna-and-tep-levels-in-colon-cancer-100645627",false,"NCT07701408","ctDNA and TEP Levels in Colon Cancer","Determination of ctDNA and TEP Levels in Patients With Colon Cancer Receiving Neoadjuvant Systemic Therapy","Inclusion Criteria:\n\n* Age 18 years or older at the time of enrollment.\n* Histologically confirmed adenocarcinoma of the colon.\n* Stage III colon cancer, defined according to the applicable TNM classification based on clinical and imaging assessment.\n* Confirmed mismatch repair (MMR) status, determined by immunohistochemistry and\u002For molecular methods.\n* Planned neoadjuvant systemic therapy according to MMR status, followed by surgical resection with curative intent.\n* ECOG performance status 0-2.\n* Ability to understand the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Stage I, II, or IV colon cancer.\n* Concurrent active malignant disease, except adequately treated non-melanoma skin cancer or carcinoma in situ.\n* Severe comorbidities or medical conditions that prevent or substantially limit neoadjuvant systemic therapy or surgical resection.\n* Known autoimmune disease requiring active immunosuppressive treatment in patients with dMMR tumors.\n* Pregnancy or breastfeeding.\n* Inability or unwillingness to provide written informed consent.","ALL","18 Years",{"count":56,"type":57},80,"ESTIMATED","INTERVENTIONAL",[60],"NA","This interventional cohort study will evaluate circulating tumor DNA (ctDNA) and tumor-educated platelets (TEP) as blood-based biomarkers in adults with stage III colon cancer who are planned to receive neoadjuvant systemic therapy followed by surgical resection.\n\nTreatment will be given according to routine clinical practice and will depend on the biological characteristics of the tumor, including mismatch repair status. Participants will provide additional blood samples at predefined time points before, during, and after treatment and surgery. These samples will be used to analyze ctDNA and TEP and to assess whether changes in these biomarkers are associated with radiological response, pathological response, and disease-free outcomes.\n\nApproximately 80 participants will be enrolled at the Institute of Oncology Ljubljana. Participants will not receive experimental drugs as part of this study.",[63],"Colon Cancer",[65,66,67,68,69],"ctDNA","Circulating Tumor DNA","Tumor-Educated Platelets","TEP","Neoadjuvant Systemic Therapy","NOT_YET_RECRUITING","2026-07-08",{"date":73,"type":74},"2026-07-14","ACTUAL",{"date":76,"type":57},"2026-08",{"date":78,"type":57},"2028-06",{"name":5,"class":6},1]